Christel Hedman1,2, Therese Djärv3,4, Peter Strang2,5, Catharina Ihre Lundgren1,4. 1. 1 Department of Molecular Medicine and Surgery, Solna, Karolinska Institutet , Stockholm, Sweden . 2. 2 Stockholms Sjukhem Foundation's R&D Department , Stockholm, Sweden . 3. 3 Department of Medicine, Solna, Karolinska Institutet , Stockholm, Sweden . 4. 4 Karolinska University Hospital , Stockholm, Sweden . 5. 5 Department of Oncology-Pathology, and Solna, Karolinska Institutet , Stockholm, Sweden .
Abstract
BACKGROUND: Differentiated thyroid cancer (DTC) has a good prognosis but a remaining risk of recurrence and need for lifelong follow-up. The aim was to study changes in health-related quality of life (HRQoL) from diagnosis to one year of follow-up. METHODS: In this prospective population-based study, patients were identified from all the Swedish departments of oncology treating DTC. In total, 487 patients diagnosed with DTC between 2012 and 2017 were invited to answer the Swedish version of the Short Form-36 Health Survey (SF-36) and a study-specific questionnaire at diagnosis and after one year. RESULTS: In total, 349 (72%) patients responded. Of these, 235 (67%) had reached one year of follow-up and also answered the questionnaire after one year. Of those, 23% had a negative view of life, and 75% had a fear of recurrence at diagnosis. These patients had a significantly lower HRQoL on eight and five of the SF-36 domains, respectively (p < 0.05). A negative view of life and a fear of recurrence also affected HRQoL negatively after one year of follow-up, with a significantly lower HRQoL on seven SF-36 domains for those reporting a negative view of life or fear of recurrence often (p < 0.05). Thyrotropin suppression did not affect HRQoL negatively. In regression models, HRQoL at diagnosis was the most important predictive factor for HRQoL at the one-year follow-up. CONCLUSIONS: Despite a good prognosis, HRQoL was substantially affected at the time of diagnosis, with some improvements after one year. As fear of recurrence and a negative view of life substantially affect HRQoL, these patients should be given additional attention.
BACKGROUND: Differentiated thyroid cancer (DTC) has a good prognosis but a remaining risk of recurrence and need for lifelong follow-up. The aim was to study changes in health-related quality of life (HRQoL) from diagnosis to one year of follow-up. METHODS: In this prospective population-based study, patients were identified from all the Swedish departments of oncology treating DTC. In total, 487 patients diagnosed with DTC between 2012 and 2017 were invited to answer the Swedish version of the Short Form-36 Health Survey (SF-36) and a study-specific questionnaire at diagnosis and after one year. RESULTS: In total, 349 (72%) patients responded. Of these, 235 (67%) had reached one year of follow-up and also answered the questionnaire after one year. Of those, 23% had a negative view of life, and 75% had a fear of recurrence at diagnosis. These patients had a significantly lower HRQoL on eight and five of the SF-36 domains, respectively (p < 0.05). A negative view of life and a fear of recurrence also affected HRQoL negatively after one year of follow-up, with a significantly lower HRQoL on seven SF-36 domains for those reporting a negative view of life or fear of recurrence often (p < 0.05). Thyrotropin suppression did not affect HRQoL negatively. In regression models, HRQoL at diagnosis was the most important predictive factor for HRQoL at the one-year follow-up. CONCLUSIONS: Despite a good prognosis, HRQoL was substantially affected at the time of diagnosis, with some improvements after one year. As fear of recurrence and a negative view of life substantially affect HRQoL, these patients should be given additional attention.
Entities:
Keywords:
TSH; fear of recurrence; population-based; prospective; quality of life; thyroid cancer
Authors: Nina Jackson Levin; Anao Zhang; David Reyes-Gastelum; Debbie W Chen; Ann S Hamilton; Bradley Zebrack; Megan R Haymart Journal: J Cancer Surviv Date: 2021-10-11 Impact factor: 4.062
Authors: Maria Papaleontiou; Josh M Evron; Nazanene H Esfandiari; David Reyes-Gastelum; Kevin C Ward; Ann S Hamilton; Francis Worden; Megan R Haymart Journal: Thyroid Date: 2020-04-16 Impact factor: 6.568
Authors: Rudolf Hoermann; John E M Midgley; Rolf Larisch; Johannes W Dietrich Journal: Front Endocrinol (Lausanne) Date: 2019-09-26 Impact factor: 5.555
Authors: Susan C Pitt; Megan C Saucke; Elizabeth M Wendt; David F Schneider; Jason Orne; Cameron L Macdonald; Nadine P Connor; Rebecca S Sippel Journal: Thyroid Date: 2020-11-04 Impact factor: 6.568
Authors: Eun Kyung Lee; Yea Eun Kang; Young Joo Park; Bon Seok Koo; Ki-Wook Chung; Eu Jeong Ku; Ho-Ryun Won; Won Sang Yoo; Eonju Jeon; Se Hyun Paek; Yong Sang Lee; Dong Mee Lim; Yong Joon Suh; Ha Kyoung Park; Hyo-Jeong Kim; Bo Hyun Kim; Mijin Kim; Sun Wook Kim; Ka Hee Yi; Sue K Park; Eun-Jae Jung; June Young Choi; Ja Seong Bae; Joon Hwa Hong; Kee-Hyun Nam; Young Ki Lee; Hyeong Won Yu; Sujeong Go; Young Mi Kang Journal: Endocrinol Metab (Seoul) Date: 2021-05-26